Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 19, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to the share buyback transaction:
- Shares Purchased: 1,450,000 ordinary shares of 25 pence each.
- Purchase Price: 1,149.15 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.04% of total voting rights).
- Shares in Issue: 5,358,282,509 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,450,000 shares purchased on May 19, 2008. Consequently, the total number of shares in issue was updated to 5,358,282,509. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the updated total number of shares in issue (5,358,282,509) for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the current percentage of Treasury shares held by the company (9.04% of total voting rights).
- Review the specific terms of the share repurchase program authorized at the May 23, 2007 Annual General Meeting.